Efficacy and safety profiles of mood stabilizers and antipsychotics for bipolar depression: a systematic review
The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Abstract
The whole picture of psychotropics for bipolar depression (BPD) remains unclear. This review compares the differences in efficacy and safety profiles among common psychotropics for BPD. MEDLINE, EMBASE, and PsycINFO were searched for proper studies. The changes in the depressive rating scale, remission/response rates, nervous system adverse events (NSAEs), gastrointestinal adverse events (GIAEs), metabolic parameters, and prolactin were compared between medication and placebo or among medications with the Cohen’s d or number needed to treat/harm. The search provided 10 psychotropics for comparison. Atypical antipsychotics (AAPs) were superior to lithium and lamotrigine at alleviating acute depressive symptoms. Lithium was more likely to induce dry mouth and nausea. Cariprazine and aripiprazole seemed to be associated with an increased risk of akathisia and upper GIAEs. Lurasidone was associated with an increased risk of developing akathisia and hyperprolactinemia. Olanzapine, olanzapine–fluoxetine combination (OFC), and quetiapine were associated with an increased risk of NSAEs, metabolic risk, dry mouth, and constipation. Cariprazine, lurasidone, OFC, or quetiapine was optimal monotherapy for BPD. Further studies are needed to assess the efficacy and safety of lamotrigine for treating BPD. Adverse events varied widely across different drug types due to variations in psychopharmacological mechanisms, dosages, titration, and ethnicities.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cai and colleagues 7 did not address lumateperone, olanzapine monotherapy, and anti depressants in their 2023 review.”
In the citing paper
“In particular, none of these studies evaluated the confidence in evidence.”
In the citing paper
“Previous reviews based on 17 studies of ten mood stabilisers and antipsychotics, 7 18 studies of six antipsychotics, 6 or 46 studies of 22 psychotropic compounds 8 either did not examine all agents or applied less rigorous approaches.”
In the citing paper
“However, evidence-based pharmacological treatments differ in their efficacy and tolerability, and available systematic reviews either focused on antipsychotics alone, 6 or did not apply metaanalysis.7”
Citations
Cites
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00136 · Cited by 10,349
Cohen, J. (1992) · Psychological Bulletin · doi:10.1037//0033-2909.112.1.155 · Cited by 8,771
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852 · cited 8×
“The guideline suggests that lithium levels equal to or more than 0.8 mEq/L are beneficial for BPD (Yatham et al., 2018).”
BackgroundMethodInfluentialCalabrese, J. R., Bowden, C. L., Sachs, G. S., Ascher, J. A., Monaghan, E., Rudd, G. D., & The Lamictal 602 Study Group (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0203 · Cited by 1,054 · cited 7×
“In published fixed-dose studies, the lamotrigine 200 mg/day group (Calabrese et al., 1999) showed a significantly increased efficacy with a moderate effect size relative to placebo (Table 1).”
BackgroundResultInfluentialTohen, M., Vieta, E., Calabrese, J., Ketter, T. A., Sachs, G., Bowden, C., Mitchell, P. B., Centorrino, F., Risser, R., Baker, R. W., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.11.1079 · Cited by 908 · cited 1×
“, 2014), OFC (Tohen et al., 2003), olanzapine (Tohen et al.”
Vieta, E., Berk, M., Schulze, T. G., Carvalho, A. F., Suppes, T., Calabrese, J. R., Gao, K., Miskowiak, K. W., & Grande, I. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.8 · Cited by 891
Calabrese, J. R., Keck, P. E., Macfadden, W., Minkwitz, M., Ketter, T. A., Weisler, R. H., Cutler, A. J., McCoy, R., Wilson, E., Mullen, J., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1351 · Cited by 883 · cited 6×
“Quetiapine-IR 300 mg/day and 600 mg/day had a similar risk for somnolence relative to placebo (Calabrese et al., 2005; Thase et al., 2006; McElroy et al., 2010; Suppes et al., 2010; Young et al., 2010; Li et al., 2016; Murasaki et al., 2018).”
BackgroundResultInfluentialMalhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
Malhi, G. S., Bell, E., Bassett, D., Boyce, P., Bryant, R., Hazell, P., Hopwood, M., Lyndon, B., Mulder, R., Porter, R., et al. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867420979353 · Cited by 614 · cited 1×
“Given clinical guidelines recommend monotherapy as the first step for treating BPD (Yatham et al., 2018; Malhi et al., 2021), this systematic review aimed to compare the efficacy (effect sizes, remission, and response rates) and safety (common adverse events in the central nervous system, gastrointestinal systems, and…”
BackgroundManagement of common adverse effects of antipsychotic medications
Stroup, T. S., & Gray, N. (2018) · World Psychiatry · doi:10.1002/wps.20567 · Cited by 572 · cited 2×
“Anticholinergic effects contribute to antipsychotic-related dry mouth and constipation, leading to clinically significant complications such as caries, erosion, periodontal disease, and ileus (Cockburn et al., 2017; Stroup and Gray, 2018).”
Background
Cited by
Yildiz, A., Siafis, S., Mavridis, D., Vieta, E., & Leucht, S. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00199-2 · Cited by 104
Antipsychotic agents in anxiety disorders: An umbrella review
Garakani, A., Buono, F. D., Salehi, M., Funaro, M. C., Klimowicz, A., Sharma, H., Faria, C. G. F., Larkin, K., & Freire, R. C. R. (2024) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13669 · Cited by 20
“61,72 Patients who have both anxiety and depression may be more responsive to the addition of low-dose antipsychotic agents in effort to manage both mood and anxiety symptoms, 72,73 especially for those who do not respond to the first line antidepressant pharmacotherapy.”
BackgroundModulating factors in mood disorders treatment
Serretti, A. (2023) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000534 · Cited by 12
Fang, Y., Huang, Y., Li, Q., Luo, Y., Xu, Q., Yang, T., Lü, X., Chen, X., Zhao, T., Huang, A., et al. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118765 · Cited by 4
Standal, K., Solbakken, O. A., Benth, J. Š., Abbass, A. A., & Heiervang, K. S. (2025) · International Journal of Social Psychiatry · doi:10.1177/00207640251390930 · Cited by 4
“(Bai et al., 2020; Cai et al., 2023; Ceraso et al., 2020; Correll et al., 2018; Croatto et al., 2023; Davies & Read, 2019; Hengartner, 2020; Horowitz et al., 2021; Jakobsen et al., 2020; Levenberg & Cordner, 2022; Moncrieff et al., 2020; Sinyor et al., 2020) and represent important concerns for…”
Metadata
- Authors
- Cai, L., Chen, G., Yang, H., & Bai, Y.
- Affiliations
- Department of Bipolar Disorder
- Shenzhen KangNing Hospital (CN)
- Corresponding author
- Cai, Luyao
- Chen, Guanjie
- Venue
- International Clinical Psychopharmacology
- Published
- 2023-03-13
- Volume
- 38
- Issue
- 4
- Pages
- 249-260
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W4353017596
- Semantic Scholar
- f856b9bfa659af28ae7e5d3b4cc3b49cc26c2e8b
- Cited by
- 11
- References
- 70
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 2 · 2023: 4
- FWCI
- 0.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- bipolar depression, mood stabilizers, antipsychotic drugs, lithium, lamotrigine, cariprazine, aripiprazole, lurasidone, olanzapine, olanzapine-fluoxetine combination, quetiapine, akathisia, hyperprolactinemia, metabolic side effects, gastrointestinal adverse effects, xerostomia, treatment efficacy, drug safety
- MeSH terms
- Lurasidone Hydrochloride, Quetiapine Fumarate, Lamotrigine, Bipolar Disorder, Humans, Lithium, Psychomotor Agitation, Antipsychotic Agents, Antimanic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety profiles of mood stabilizers and antipsychotics for bipolar depression: a systematic review. https://app.cochat.ai/papers/10.1097/yic.0000000000000449
- The paper
- Cai, L., Chen, G., Yang, H., & Bai, Y. (2023). Efficacy and safety profiles of mood stabilizers and antipsychotics for bipolar depression: a systematic review. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0000000000000449
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.